Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIB extension study of FLUAD vs Agrippal S1 in previously vaccinated children
2010-021644-18Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in influenza comparing FLUAD with Agrippal S1 (2 arms). Primary endpoints: Immunogenicity per CHMP criteria in FLUAD-primed children receiving FLUAD booster, Immunogenicity per CBER criteria in FLUAD-primed children receiving FLUAD booster and 1 more. Started Jul 2010; status: completed.
02
Drugs
Fluzone Trivalentinfluenza vaccine, inactivated, surface antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-021644-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021644-18.